Pluri Biotech

02/06/2026

Exciting progress for Pluri and Cellav:
With the completion of U.S. cosmetic product listings, our subsidiary Cellav is now moving toward commercial launch in the United States, marking an important transition from development to commercialization.

Two regenerative aesthetic products, with clinically validated ingredients, are expected to enter the U.S. market in 2026, as we build partnerships with distributors, clinics, and strategic partners.
Today, that technology moves from the lab to the market,

Well done Katty Bishara Dweiry!

26/03/2026

Big news from Pluri Inc.! 🚀
Our Chairman of the Board, Alejandro Weinstein, is doubling down on his commitment to Pluri’s future with an additional $2.5 million investment-at a 30% premium to the market price!
This investment is a powerful signal of confidence in our team, our technology, and our mission to solve global challenges through cell-based solutions. As CEO Yaky Yanay noted, we are focused on unlocking the immense value within our platform to benefit our shareholders and the world.
Stay tuned as we continue to push the boundaries of biotechnology!

Read more: https://eur05.safelinks.protection.outlook.com/?url=https%3A%2F%2Fpluri-biotech.com%2Freleases%2Fpluri-secures-additional-investment-from-chairman-alejandro-weinstein-at-30-premium-to-market-in-a-private-placement%2F&data=05%7C02%7Cnofargl%40Pluri-biotech.com%7C429d557d505843696f4d08de8b464c6e%7Cdddc407fde4d434984cbc328e55f7e8a%7C0%7C0%7C639101331221350281%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=jswpOAeIoo5wlcxJMJTb1sFLgZWRDtvmjw%2F8muCIpCo%3D&reserved=0
$PLUR

Haifa, Israel – March 26, 2026 – Pluri Inc. (“Pluri” or the “Company”) (Nasdaq, TASE: PLUR), a biotechnology company leveraging a proprietary cell-based platform across multiple commercial verticals, today announced that an entity beneficially owned by Alejandro Weinstein, Chairman of th...